{"nctId":"NCT01785875","briefTitle":"Extension Study of Etelcalcetide in the Treatment of Secondary Hyperparathyroidism (SHPT) in Patients With Chronic Kidney Disease (CKD) on Hemodialysis","startDateStruct":{"date":"2013-07-31","type":"ACTUAL"},"conditions":["Hyperparathyroidism, Secondary"],"count":891,"armGroups":[{"label":"Etelcalcetide","type":"EXPERIMENTAL","interventionNames":["Drug: Etelcalcetide"]}],"interventions":[{"name":"Etelcalcetide","otherNames":["AMG 416"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Subject understands the study procedures and agrees to participate in the study by giving written informed consent.\n* Subject must complete the treatment and follow-up period, or have been discontinued for rising intact parathyroid hormone (iPTH), from an AMG 416 phase 3 parent study prior to the start of dosing in this study: 20120229 (NCT01785849), 20120230 (NCT01788046), or 20120359 (NCT01932970).\n* Subject agrees to not participate in another study of an investigational agent during the study.\n* Other Inclusion Criteria may apply\n\nExclusion Criteria:\n\n* Currently receiving treatment in another investigational device or drug study.\n* Currently receiving other investigational procedures while participating in this study.\n* Subject has known sensitivity to any of the products or components to be administered during dosing.\n* Subject has an unstable medical condition based on medical history, physical examination, and routine laboratory tests, or is otherwise unstable in the judgment of the Investigator.\n\nOther Exclusion Criteria may apply","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","maximumAge":"100 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Number of Participants With Adverse Events (AEs)","description":"Treatment-related adverse events are those the investigator indicated as having a reasonable possibility of having been caused by etelcalcetide. A serious adverse event is defined as an adverse event that meets at least 1 of the following serious criteria: • fatal • life threatening • requires in-patient hospitalization or prolongation of existing hospitalization • results in persistent or significant disability/incapacity • congenital anomaly/birth defect • other medically important serious event.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"354","spread":null},{"groupId":"OG001","value":"337","spread":null},{"groupId":"OG002","value":"108","spread":null},{"groupId":"OG003","value":"799","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"161","spread":null},{"groupId":"OG001","value":"142","spread":null},{"groupId":"OG002","value":"53","spread":null},{"groupId":"OG003","value":"356","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"215","spread":null},{"groupId":"OG001","value":"141","spread":null},{"groupId":"OG002","value":"36","spread":null},{"groupId":"OG003","value":"392","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"6","spread":null},{"groupId":"OG001","value":"5","spread":null},{"groupId":"OG002","value":"2","spread":null},{"groupId":"OG003","value":"13","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"22","spread":null},{"groupId":"OG001","value":"11","spread":null},{"groupId":"OG002","value":"8","spread":null},{"groupId":"OG003","value":"41","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"27","spread":null},{"groupId":"OG001","value":"16","spread":null},{"groupId":"OG002","value":"8","spread":null},{"groupId":"OG003","value":"51","spread":null}]}]}]},{"type":"PRIMARY","title":"Number of Participants With Shift in Laboratory Values From Baseline Grade 0 or 1 to Post-baseline Grade 3 or 4","description":"Laboratory toxicity grading was based on Common Terminology Criteria for Adverse Events (CTCAE) version 4.0, where Grade 0 represents values in the normal range and grade 4 represents values with life-threatening consequences and urgent intervention indicated.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"51","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"77","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"69","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null}]}]}]},{"type":"PRIMARY","title":"Number of Participants Who Developed Anti-etelcalcetide Antibodies","description":"A validated dual flow-cell biosensor immunoassay was used to detect antibodies capable of binding etelcalcetide. The number of participants with a negative or no result at baseline and positive binding antibodies at any time post-baseline is reported.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"10","spread":null},{"groupId":"OG001","value":"15","spread":null},{"groupId":"OG002","value":"2","spread":null},{"groupId":"OG003","value":"27","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With > 30% Reduction From Baseline in PTH During the Efficacy Assessment Phase","description":"The efficacy assessment phase (EAP) is defined as the last 6 weeks before ending treatment, which was only for participants who completed a minimum of 8 weeks of treatment with etelcalcetide. If multiple assessments were available during the EAP, values were averaged.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"81.2","spread":null},{"groupId":"OG001","value":"54.5","spread":null},{"groupId":"OG002","value":"65.1","spread":null},{"groupId":"OG003","value":"67.7","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With > 30% Reduction From Baseline in PTH During the EAP12","description":"The efficacy assessment phase at 12 months (EAP12) was defined as the period from week 46 to 53 (inclusive). If multiple assessments were available during the EAP12, values were averaged.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"82.5","spread":null},{"groupId":"OG001","value":"53.3","spread":null},{"groupId":"OG002","value":"63.5","spread":null},{"groupId":"OG003","value":"67.5","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With PTH ≤ 300 pg/mL During the EAP","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"55.7","spread":null},{"groupId":"OG001","value":"59.7","spread":null},{"groupId":"OG002","value":"54.6","spread":null},{"groupId":"OG003","value":"57.3","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With PTH ≤ 300 pg/mL During the EAP12","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"54.8","spread":null},{"groupId":"OG001","value":"61.1","spread":null},{"groupId":"OG002","value":"42.7","spread":null},{"groupId":"OG003","value":"56.4","spread":null}]}]}]},{"type":"SECONDARY","title":"Percent Change From Baseline in Mean PTH During the EAP","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-54.55","spread":"2.12"},{"groupId":"OG001","value":"3.92","spread":"8.68"},{"groupId":"OG002","value":"-28.40","spread":"6.96"},{"groupId":"OG003","value":"-26.07","spread":"4.04"}]}]}]},{"type":"SECONDARY","title":"Percent Change From Baseline in Mean PTH During the EAP12","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-55.41","spread":"2.20"},{"groupId":"OG001","value":"4.78","spread":"9.62"},{"groupId":"OG002","value":"-27.05","spread":"7.57"},{"groupId":"OG003","value":"-25.59","spread":"4.59"}]}]}]},{"type":"SECONDARY","title":"Percent Change From Baseline in Mean Corrected Calcium During the EAP","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-10.01","spread":"0.52"},{"groupId":"OG001","value":"-6.74","spread":"0.47"},{"groupId":"OG002","value":"-8.65","spread":"1.04"},{"groupId":"OG003","value":"-8.41","spread":"0.34"}]}]}]},{"type":"SECONDARY","title":"Percent Change From Baseline in Mean Corrected Calcium During the EAP12","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-9.76","spread":"0.52"},{"groupId":"OG001","value":"-6.43","spread":"0.45"},{"groupId":"OG002","value":"-9.73","spread":"1.14"},{"groupId":"OG003","value":"-8.25","spread":"0.34"}]}]}]},{"type":"SECONDARY","title":"Percent Change From Baseline in Mean Corrected Calcium Phosphorus Product During the EAP","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-15.26","spread":"1.58"},{"groupId":"OG001","value":"-10.41","spread":"1.61"},{"groupId":"OG002","value":"-6.58","spread":"4.28"},{"groupId":"OG003","value":"-12.04","spread":"1.13"}]}]}]},{"type":"SECONDARY","title":"Percent Change From Baseline in Mean Corrected Calcium Phosphorus Product During the EAP12","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-15.30","spread":"1.53"},{"groupId":"OG001","value":"-9.78","spread":"1.62"},{"groupId":"OG002","value":"-7.29","spread":"4.82"},{"groupId":"OG003","value":"-11.95","spread":"1.13"}]}]}]},{"type":"SECONDARY","title":"Percent Change From Baseline in Mean Phosphorus During the EAP","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-5.71","spread":"1.71"},{"groupId":"OG001","value":"-3.50","spread":"1.68"},{"groupId":"OG002","value":"2.82","spread":"4.56"},{"groupId":"OG003","value":"-3.62","spread":"1.20"}]}]}]},{"type":"SECONDARY","title":"Percent Change From Baseline in Mean Phosphorus During the EAP12","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-5.87","spread":"1.65"},{"groupId":"OG001","value":"-3.06","spread":"1.73"},{"groupId":"OG002","value":"3.53","spread":"5.46"},{"groupId":"OG003","value":"-3.59","spread":"1.22"}]}]}]},{"type":"PRIMARY","title":"Change From Baseline in Blood Pressure","description":"Blood pressure (BP) values were taken post-hemodialysis assessments.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"4.0","spread":"1.5"},{"groupId":"OG001","value":"4.5","spread":"1.4"},{"groupId":"OG002","value":"-5.5","spread":"2.8"},{"groupId":"OG003","value":"2.9","spread":"1.0"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3.5","spread":"1.6"},{"groupId":"OG001","value":"6.5","spread":"1.5"},{"groupId":"OG002","value":"-6.8","spread":"3.0"},{"groupId":"OG003","value":"3.8","spread":"1.0"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.2","spread":"0.8"},{"groupId":"OG001","value":"1.2","spread":"0.9"},{"groupId":"OG002","value":"-5.1","spread":"1.5"},{"groupId":"OG003","value":"0.8","spread":"0.6"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.1","spread":"0.9"},{"groupId":"OG001","value":"0.8","spread":"0.9"},{"groupId":"OG002","value":"-2.6","spread":"1.7"},{"groupId":"OG003","value":"0.6","spread":"0.6"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":161,"n":383},"commonTop":["Blood calcium decreased","Diarrhoea","Vomiting","Nausea","Muscle spasms"]}}}